{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:17:07Z","timestamp":1790144227230,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":1782,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13311-018-0668-6","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T21:28:32Z","timestamp":1537565312000},"page":"1032-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?"],"prefix":"10.1016","volume":"15","author":[{"given":"Saak Victor","family":"Ovsepian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie Br\u00edd","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1007\/s13311-018-0668-6_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jalz.2018.01.011","article-title":"Synaptic vesicle cycle and amyloid beta: Biting the hand that feeds","volume":"14","author":"Ovsepian","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1007\/s13311-018-0668-6_bib2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","article-title":"The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease","volume":"82","author":"Spires-Jones","year":"2014","journal-title":"Neuron"},{"issue":"2","key":"10.1007\/s13311-018-0668-6_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"3","key":"10.1007\/s13311-018-0668-6_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/0929866043407174","article-title":"Oligomers in the brain: The emerging role of soluble protein aggregates in neurodegeneration","volume":"11","author":"Walsh","year":"2004","journal-title":"Protein and Peptide Letters"},{"issue":"3","key":"10.1007\/s13311-018-0668-6_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.emboj.7600061","article-title":"Take five\u2013BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation","volume":"23","author":"Haass","year":"2004","journal-title":"EMBO J"},{"issue":"41","key":"10.1007\/s13311-018-0668-6_bib6","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","article-title":"The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential","volume":"29","author":"Vassar","year":"2009","journal-title":"J Neurosci"},{"issue":"12","key":"10.1007\/s13311-018-0668-6_bib7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802611795860942","article-title":"gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes","volume":"11","author":"Imbimbo","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1007\/s13311-018-0668-6_bib8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"18","key":"10.1007\/s13311-018-0668-6_bib9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-018-0668-6_bib10","first-page":"155","article-title":"BACE inhibitor bust in Alzheimer trial","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1007\/s13311-018-0668-6_bib11","first-page":"385","article-title":"BACE failures lower AD expectations, again","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1007\/s13311-018-0668-6_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cell.2014.10.016","article-title":"Lessons from a failed gamma-secretase Alzheimer trial","volume":"159","author":"De Strooper","year":"2014","journal-title":"Cell"},{"issue":"Pt A","key":"10.1007\/s13311-018-0668-6_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of Alzheimer's disease: Past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1007\/s13311-018-0668-6_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1073858415588264","article-title":"Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission","volume":"22","author":"Ovsepian","year":"2016","journal-title":"Neuroscientist"},{"key":"10.1007\/s13311-018-0668-6_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1741-7015-7-7","article-title":"Recent developments in Alzheimer's disease therapeutics","volume":"7","author":"Rafii","year":"2009","journal-title":"BMC Med"},{"issue":"15","key":"10.1007\/s13311-018-0668-6_bib16","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1523\/JNEUROSCI.4668-14.2015","article-title":"Arginine Deprivation and Immune Suppression in a Mouse Model of Alzheimer's Disease","volume":"35","author":"Kan","year":"2015","journal-title":"Journal of Neuroscience"},{"issue":"2","key":"10.1007\/s13311-018-0668-6_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.1984.2.2.124","article-title":"Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine\u2013an inhibitor of polyamine biosynthesis","volume":"2","author":"Abeloff","year":"1984","journal-title":"J Clin Oncol"},{"issue":"8573","key":"10.1007\/s13311-018-0668-6_bib18","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(87)91131-7","article-title":"Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness","volume":"2","author":"Pepin","year":"1987","journal-title":"Lancet"},{"key":"10.1007\/s13311-018-0668-6_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-018-0669-5","article-title":"L-norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer's Disease","author":"Polis","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1007\/s13311-018-0668-6_bib20","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.neurobiolaging.2003.08.012","article-title":"Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease","volume":"24","author":"Oddo","year":"2003","journal-title":"Neurobiology of Aging"},{"issue":"3","key":"10.1007\/s13311-018-0668-6_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A beta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"issue":"6","key":"10.1007\/s13311-018-0668-6_bib22","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.clnu.2016.09.031","article-title":"Supplementing essential amino acids with the nitric oxide precursor, l-arginine, enhances skeletal muscle perfusion without impacting anabolism in older men","volume":"36","author":"Mitchell","year":"2017","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1007\/s13311-018-0668-6_bib23","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1073\/pnas.0610207104","article-title":"Low-dose L-arginine administration increases microperfusion of hindlimb muscle without affecting blood pressure in rats","volume":"104","author":"Ohta","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1007\/s13311-018-0668-6_bib24","doi-asserted-by":"crossref","first-page":"1602s","DOI":"10.1093\/jn\/137.6.1602S","article-title":"Arginine metabolism: Boundaries of our knowledge","volume":"137","author":"Morris","year":"2007","journal-title":"Journal of Nutrition"},{"key":"10.1007\/s13311-018-0668-6_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3360001","article-title":"Arginine metabolism: nitric oxide and beyond","volume":"336","author":"Wu","year":"1998","journal-title":"Biochemical Journal"},{"key":"10.1007\/s13311-018-0668-6_bib26","series-title":"The Beautiful Brain: The Drawings of Ramon y Cajal","author":"DeFelipe","year":"2017"},{"issue":"5","key":"10.1007\/s13311-018-0668-6_bib27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.conb.2010.06.005","article-title":"Astrocyte heterogeneity: an underappreciated topic in neurobiology","volume":"20","author":"Zhang","year":"2010","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"10.1007\/s13311-018-0668-6_bib28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3233\/JAD-2010-100630","article-title":"Is the Urea Cycle Involved in Alzheimer's Disease?","volume":"21","author":"Hansmannel","year":"2010","journal-title":"Journal of Alzheimers Disease"},{"issue":"6","key":"10.1007\/s13311-018-0668-6_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tips.2015.03.006","article-title":"Arginase: an old enzyme with new tricks","volume":"36","author":"Caldwell","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"10.1007\/s13311-018-0668-6_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.295","article-title":"Arginase 2 promotes neurovascular degeneration during ischemia\/reperfusion injury","volume":"7","author":"Shosha","year":"2016","journal-title":"Cell Death Dis"},{"issue":"1\u20132","key":"10.1007\/s13311-018-0668-6_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2015.10.140","article-title":"Identification of elevated urea as a severe, ubiquitous metabolic defect in the brain of patients with Huntington's disease","volume":"468","author":"Patassini","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-018-0668-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T19:46:27Z","timestamp":1728675987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1878747923010309"],"URL":"https:\/\/doi.org\/10.1007\/s13311-018-0668-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-018-0668-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}